Reduction of conspicuous facial pores by topical fullerene: Possible role in the suppression of PGE2 production in the skin

Journal of Nanobiotechnology

Volumn 12, Issue 1, 2014, Pages

  Inui, Shigeki ^a   Mori, Ayako ^b   Ito, Masayuki ^c   Hyodo, Sayuri ^c   Itami, Satoshi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b Clinic Mori   (Japan)

^c Vitamin C60 BioResearch Corporation   (Japan)

Author keywords

Cosmeceutical; Facial pore; Fullerene; Melanin; Prostaglandin E2

Indexed keywords

COSMECEUTICAL; COSMECEUTICALS; FACIAL PORE; HUMAN EPIDERMIS; MANN-WHITNEY U-TEST; PROSTAGLANDIN E2; SELF-ADMINISTERED QUESTIONNAIRE; THERAPEUTIC TARGETS;

LIPIDS; MELANIN;

FULLERENES;

COSMETIC; FULLERENE; PROSTAGLANDIN E2; RADICAL SPONGE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONSPICUOUS FACIAL PORE; CONTROLLED STUDY; EPIDERMIS; FEMALE; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; IRRADIATION; JAPANESE; LOTION; MIDDLE AGED; NORMAL HUMAN; QUESTIONNAIRE; RECONSTRUCTED HUMAN EPIDERMIS; SKIN SURFACE; ULTRAVIOLET B RADIATION; WILCOXON SIGNED RANKS TEST;

ADMINISTRATION, TOPICAL; ADULT; AGED; COSMETICS; DINOPROSTONE; FEMALE; FULLERENES; HUMANS; MIDDLE AGED; SKIN; ULTRAVIOLET RAYS;

EID: 84896821607     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-12-6     Document Type: Article

References (9)

1. Inui S, Itami S. Perifollicular pigmentation is the first target for topical vitamin C derivative ascorbyl 2-phosphate 6-palmitate (APPS): randomized, single-blinded, placebo-controlled study. J Dermatol 2007, 34:221-223. 10.1111/j.1346-8138.2007.00256.x, 17291309.
2. Saedi N, Petrell K, Arndt K, Dover J. Evaluating facial pores and skin texture after low-energy nonablative fractional 1440-nm laser treatments. J Am Acad Dermatol 2013, 68:113-118. 10.1016/j.jaad.2012.08.041, 23098639.
3. Hermanns JF, Petit L, Martalo O, Pierard-Franchimont C, Cauwenbergh G, Pierard GE. Unraveling the patterns of subclinical pheomelanin-enriched facial hyperpigmentation: effect of depigmenting agents. Dermatology 2000, 201:118-122. 10.1159/000018473, 11053913.
4. Scott G, Leopardi S, Printup S, Malhi N, Seiberg M, Lapoint R. Proteinase-activated receptor-2 stimulates prostaglandin production in keratinocytes: analysis of prostaglandin receptors on human melanocytes and effects of PGE2 and PGF2alpha on melanocyte dendricity. J Invest Dermatol 2004, 122:1214-1224. 10.1111/j.0022-202X.2004.22516.x, 15140225.
5. Starner RJ, McClelland L, Abdel-Malek Z, Fricke A, Scott G. PGE(2) is a UVR-inducible autocrine factor for human melanocytes that stimulates tyrosinase activation. Exp Dermatol 2010, 19:682-684. 10.1111/j.1600-0625.2010.01074.x, 3649002, 20500768.
6. Xiao L, Matsubayashi K, Miwa N. Inhibitory effect of the water-soluble polymer-wrapped derivative of fullerene on UVA-induced melanogenesis via downregulation of tyrosinase expression in human melanocytes and skin tissues. Arch Dermatol Res 2007, 299:245-257. 10.1007/s00403-007-0740-2, 17333222.
7. Terazawa S, Nakajima H, Shingo M, Niwano T, Imokawa G. Astaxanthin attenuates the UVB-induced secretion of prostaglandin E2 and interleukin-8 in human keratinocytes by interrupting MSK1 phosphorylation in a ROS depletion-independent manner. Exp Dermatol 2012, 21(Suppl 1):11-17.
8. Kawada A, Noda T, Hiruma M, Ishibashi A, Arai S. The relationship of sun protection factor to minimal erythema dose, Japanese skin type, and skin color. J Dermatol 1993, 20:514-516.
9. Duval C, Regnier M, Schmidt R. Distinct melanogenic response of human melanocytes in mono-culture, in co-culture with keratinocytes and in reconstructed epidermis, to UV exposure. Pigment Cell Res 2001, 14:348-355. 10.1034/j.1600-0749.2001.140506.x, 11601656.